Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives
Theodora Anagnostou, Mark R Litzow Mayo Clinic Rochester, Rochester, MN, USA Abstract: Ponatinib, a third-generation tyrosine kinase inhibitor that inhibits BCR/ABL independent of the mutation status, is currently approved for the treatment of patients with chronic myeloid leukemia or acute...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-12-01
|
| Series: | Blood and Lymphatic Cancer : Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/spotlight-on-ponatinib-in-the-treatment-of-chronic-myeloid-leukemia-an-peer-reviewed-article-BLCTT |